Complement C1q does not bind monomeric β-amyloid

Experimental Neurology

Volumn 128, Issue 1, 1994, Pages 136-142

  Snyder, S W ^a   Wang, G T ^a   Barrett, L ^a   Ladror, R U S ^a   Casuto, D ^a   Lee, F C M ^a   Krafft, G A ^a   Holzman, R B ^a   Holzman, T F ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0027966134     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1994.1121     Document Type: Article

References (32)

1. Chartier-Harlin, M., F. Crawford, H. Houlden, A. Warren, D. Hughes, L. Fidani, A. M. Goate, M. Rossor, P. Roques, J. Hardy, and M. J. Mullan. 1991. Early-onset Alzheimer’s disease caused by mutations at codon 717 of the ß-amyloid precursor protein gene. Nature 353: 844-846.
2. CITRON, M., T. OLTERSDORF, C. HAASS, L. MCCONLOGUE, A. Y. HUNG, P. SEUBERT, C. VIG-OPELFREY, I. LIEBERBURG, and D. J. SELKOE. 1992. Mutation of the ß-amyloid precursor protein in familial Alzheimer’s disease increases ß-protein production. Nature 360:672-674.
3. DICKSON, D. W., and J. ROGERS. 1992. Neuroimmunology of Alzheimer’s disease: A conference report. Neurobiol. Aging 13: 793-798.
4. GLENNER, G. G., and C. W. WONG. 1984. Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120:885-890.
5. Goate, A. M., M. Chartier-Harlin, M. J. Mullan, J. Brown, F. Crawford, L. Fidani, L. Giuffra, A. R. Haynes, N. Irving, L. A. James, R. Mant, P. Newton, K. Rooke, P. Roques, C. Talbot, M. A. Pericak-Vance, A. D. Roses, R. Williamson, M. N. Rossor, M. J. Owen, and J. Hardy. 1991. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 349: 704-706.
6. GOLDGABER, D., M. I. LERMAN, W. O. MCBRIDE, U. SAFFIOTTI, and C. D. GAJDUSEK. 1987. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer’s disease. Science 235: 877-880.
7. Hendriks, L., C. M. Van Duijn, P. Cras, M. Cruts, W. Van Hul, F. Van Harskamp, A. Warren, M. G. McInnis, S. E. Antonara-kis, J. J. Martin, A. Hofman, and C. Van Broeckhoven. 1992. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the ß-amyloid precursor protein gene. Nature Genet. 1: 218-221.
8. HOLZMAN, T. F., and S. W. SNYDER. 1994. Applications of analytical ultracentrifugation in structure-based drug design. In: Modern Analytical Ultracentrifugation: Acquisition and Interpretation of Data for Biological and Synthetic Polymer Systems (T. M. Schuster, Ed.). Springer-Verlag, Boston.
9. Jarrett, J. T., E. P. Berger, and P. T. Lansbury Jr. 1993. The carboxy terminus of the beta-amyloid protein is critical for the seeding of amyloid formation-Implications for the pathogenesis of Alzheimer s-disease. Biochemistry 32: 4693-4697.
10. Jiang, H., J. N. Siegel, and H. Gewurz. 1991. Binding and complement activation by C-reactive protein via the collagen-like region of Clq and inhibition of these reactions by monoclonal antibodies to C-reactive protein and Clq. J. Immunol. 146: 2324-2330.
11. Jiang, H., B. Cooper, F. A. Robey, and H. Gewurz. 1992. DNA binds and activates complement via residues 14-26 of the human Clq A chain. J. Biol. Chem. 267: 25597-25601.
12. Kang, J., H. Lemaire, A. Unterbeck, J. M. Salbaum, C. L. Masters, K. H. Grzeschik, G. Multhaup, K. Beyreuther, and B. Muller-Hill. 1987. The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733-736.
13. Kitaguchi, N., Y. Takahashi, Y. Tokushima, S. Shiojiri, and H. Ito. 1988. Novel precursor of Alzheimer’s disease amyloid protein shows protease inhibitory activity. Nature 331: 530-532.
14. Kirschner, D. A., H. Inouye, L. K. Duffy, A. Sinclair, M. Lind, and D. J. Selkoe. 1987. Synthetic peptide homologous to beta protein from Alzheimer disease from amyloid-like fibrils in vitro. Proc. Natl. Acad. Sci. USA 84: 6953-6957.
15. Krafft, G. A. 1993. Perspectives on amyloid and Alzheimer’s disease: A critical review. Annu. Rep. Med. Chem. 28: 49-58.
16. Loos, M. 1982. The classical complement pathway: Mechanism of activation of the first component by antigen-antibody complexes. Prog. Allergy 30: 115-192.
17. Lue, L., and J. Rogers. 1992. Full complement activation fails in diffuse plaques of the Alzheimer’s disease cerebellum. Dementia 3:308-313.
18. Mullan, M. J., F. Crawford, K. Axelman, H. Houlden, L. Lilius, B. Winblad, and L. Lannfelt. 1992. A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N-terminus of ß-amyloid. Nature Genet. 1: 345-347.
19. Müller-Eberhard, H. J. 1988. Molecular organization and function of the complement system. Annu. Rev. Biochem. 57: 321-347.
20. Murrell, J., M. Farlow, B. Ghetti, and M. D. Benson. 1991. A mutation in the amyloid precursor protein associated with hereditary Alzheimer’s disease. Science 254: 97-99.
21. Ponte, P., P. Gonzalez-Dewhitt, J. Schilling, J. Miller, D. Hsu, B. Greenberg, K. Davis, W. Wallace, I. Lieberburg, and F. Fuller. 1988. A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. Nature 331: 525-527.
22. Poon, P. H., M. L. Phillips, and V. N. Schumaker. 1985. Immunoglobulin M possesses two binding sites for complement subcomponent Clq, and soluble 1:1 and 2:1 complexes are formed in solution at reduced ionic strength. J. Biol. Chem. 260: 9357-9365.
23. Rogers, J., N. R. Cooper, S. Webster, J. Schultz, P. L. McGeer, S. D. Styren, Civinwh, L. Brachova, B. Bradt, P. Ward, et al. 1992. Complement activation by beta-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 89:10016-10020.
24. Rogers, J., J. Schults, L. Brachova, L. Lue, S. Webster, B. Bradt, N. R. Cooper, and D. E. Moss. 1992. Complement activation and ß-amyloid-mediated neurotoxicity in Alzheimer’s disease. Res. Immunol. 143: 624-630.
25. Snyder, S. W., U. S. Ladror, G. T. Wang, G. A. Krafft, and T. F. Holzman. 1993. Kinetics of beta-amyloid aggregate formation. Biophys. J. 64: A378. [Abstract].
26. Snyder, S. W., U. S. Ladror, G. T. Wang, G. A. Krafft, and T. F. Holzman. 1993. Hydrodynamic studies of the aggregation behavior of beta-amyloid. Biophys. J. 64: A378. [Abstract].
27. Snyder, S. W., U. S. Ladror, G. T. Wang, G. A. Krafft, and T. F. Holzman. 1993. Specific inhibition of beta-amyloid 1-42 aggregation by beta-amyloid 1-40. Soc. Neurosci. Abstr. 19: 1635. [Abstract].
28. Snyder, S. W., U. S. Ladror, W. S. Wade, L. W. Barrett, G. T. Wang, H. J. Huffaker, E. D. Matayoshi, G. A. Krafft, and T. F. Holzman. 1994. Amyloid-ß aggregation: Selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys. J., in press.
29. Steinberg, I. Z., and H. K. Schachman. 1966. Ultracentrifugation studies with absorption optics. V. Analysis of interacting systems involving macromolecules and small molecules. Biochemistry 5: 3728-3747.
30. Tanzi, R. E., A. I. McClatchey, E. D. Lamperti, L. Villa-Komaroff, J. F. Gusella, and R. L. Neve. 1988. Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer’s disease. Nature 331: 528-530.
31. Webster, S. D., and J. Rogers. 1993. Acceleration of ß-amyloid peptide aggregation by Clq. Soc. Neurosci. Abstr 19: 19. [Abstract].
32. Yankner, B. A., L. K. Duffy, and D. A. Kirschner. 1990. Neurotrophic and neurotoxic effects of amyloid ß protein: Reversal by tachykinin neuropeptides. Science 250: 279-282.